%0 Case Reports %T Case report and literature review of BRAF-V600 inhibitors for treatment of papillary craniopharyngiomas: A potential treatment paradigm shift. %A Nussbaum PE %A Nussbaum LA %A Torok CM %A Patel PD %A Yesavage TA %A Nussbaum ES %J J Clin Pharm Ther %V 47 %N 6 %D Jun 2022 %M 35023192 %F 2.145 %R 10.1111/jcpt.13600 %X OBJECTIVE: The BRAF-V600E genetic mutation offers a potential targeted therapy for the treatment of papillary craniopharyngiomas.
METHODS: A 35-year-old man underwent a craniotomy and subtotal resection of a large BRAF-V600E-positive papillary craniopharyngioma before referral to our institution. Our treatment included the BRAF-V600 inhibitor dabrafenib mesylate (75 mg, twice/day) and trametinib dimethyl sulfoxide (2 mg/day). The residual tumour decreased in size by 95% over 21 months without negative side effects.
CONCLUSIONS: We reviewed the literature on BRAF-V600E inhibition as a non-invasive method of treating papillary craniopharyngiomas harbouring the BRAF-V600E mutation.